| Trial ID: | L5813 |
| Source ID: | NCT04634500
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
| Acronym: |
ENHANCE-M
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM (Type 2 Diabetes Mellitus)
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: Change from baseline in HbA1c, at 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Daewoong Pharmaceutical Co. LTD.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2020-11-18
|
| Completion Date: |
2021-11-03
|
| Results First Posted: |
|
| Last Update Posted: |
2022-10-25
|
| Locations: |
Daewoong pharmatceutical, Soeul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT04634500
|
